scispace - formally typeset
B

Barbara Handelin

Researcher at Massachusetts Institute of Technology

Publications -  5
Citations -  1958

Barbara Handelin is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: Gene & Chromosome 19. The author has an hindex of 4, co-authored 4 publications receiving 1906 citations.

Papers
More filters
Journal ArticleDOI

Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor

TL;DR: Together the hMR and hGR provide unexpected functional diversity in which hormone-binding properties, target gene interactions, and patterns of tissue-specific expression may be used in a combinatorial fashion to achieve complex physiologic control.
Journal ArticleDOI

Monochromosomal rodent-human hybrids from microcell fusion of human lymphoblastoid cells containing an inserted dominant selectable marker.

TL;DR: An improved system for the production of a series of rodent-human hybrids selectively retaining single human chromosomes marked in known locations is described, which has significant applications in gene mapping and other genetic studies.
Journal ArticleDOI

Generation and characterization of irradiation hybrids of human chromosome 4

TL;DR: A modification of the method first developed by Goss and Harris for generation of irradiation hybrids used to obtain new polymorphic markers for Huntington's disease and identified 41 single-copy fragments, of which 27 have been mapped to specific regions of chromosome 4.
Journal ArticleDOI

Analysis of human chromosome 11 by somatic cell genetics: Reexamination of derivatives of human-hamster cell line J1

TL;DR: The data presented here suggest that in several hybrid derivatives of J1, a continuous DNA segment of approximately 107base pairs in length which includes the insulin and HRAS1 genes has been isolated from the remainder of the human genome.
Book ChapterDOI

Chapter 12. Adapting Payers’ and Producers’ Incentives to Drug Repurposing

TL;DR: In this article , the authors describe the considerations of payers and how these translate to signals for research and development by producers, and elaborate a business model that exchanges some of the profit motives with the prioritisation of medical value.